On Wednesday, Costco Wholesale Corporation (NASDAQ:COST)’s shares inclined 0.12% to $162.39.
COST has beta value of 0.54. The company has the market capitalization of $71.03 billion. Return on assets ratio of the company was 7.00% while its return on equity ratio was 21.70%. ATR value of company was 2.45 while stock volatility for week was 1.17% while for month was 1.43%. Debt to equity ratio of the company was -0.58 and its current ratio was 1.00.
The mean estimate for the short term price target for Costco Wholesale Corporation(NASDAQ:COST) stands at $163.48 according to 23 Analysts. The higher price target estimate for the stock has been calculated at $185.00 while the lower price target estimate is at $136.00.
Analysts mean recommendation for the stock is 2.10. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Costco Wholesale Corporation (Costco) is engaged in the operation of membership warehouses in the United States (U.S.) and Puerto Rico, Canada, United Kingdom (U.K.), Mexico, Japan, Australia, Spain, and through majority-owned subsidiaries in Taiwan and Korea.
PDL BioPharma Inc (NASDAQ:PDLI)’s shares gained 0.76% to $3.97.
PDLI offered 11.70% EPS for prior five years. The company has 56.50% return on equity value while its ROI ratio was 39.60%. The company has $649.39 million market capitalizations and the institutional ownership was 87.70%. Its price to book ratio was 1.09. Volatility of the stock was 2.82% for the week while for the month booked as 4.46%.
The mean estimate for the short term price target for PDL BioPharma Inc (NASDAQ:PDLI) stands at $5.75 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $6.00 while the lower price target estimate is at $5.50.
Analysts mean recommendation for the stock is 3.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired.
At the end of Wednesday’s trade, 21Vianet Group Inc (NASDAQ:VNET)‘s shares dipped -0.50% to $20.02.
VNET is currently valued at $1.73 billion. The company has 346.80 million shares outstanding and 70.70% shares of the company were owned by institutional investors. The company has 3.29 value in price to sale ratio while price to book ratio was recorded as 2.54. The company exchanged hands with 2.11 million shares as compared to its average daily volume of 737,000 shares. It beta stands at 1.02.
The mean estimate for the short term price target for 21Vianet Group Inc (NASDAQ:VNET) stands at $25.09 according to 6 Analysts. The higher price target estimate for the stock has been calculated at $33.98. while the lower price target estimate is at $20.99.
Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
21Vianet Group, Inc. is a carrier-neutral Internet data center services provider in China. The Company hosts its customers’ servers and networking equipment and provides interconnectivity to improve the performance, availability and security of their Internet infrastructure.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.